Trachoma remains the leading infectious cause of blindness globally, concentrate...
Africa Trials
5
US Trials
580
Gap Ratio
116x
Nations
54
Key Finding
Africa hosted 5 trachoma trials versus 580 in the United States, a 116-fold disparity in research investment.
Regional Comparison
Distribution Analysis
Inequality Profile
Temporal & Structural
Why It Matters
Trachoma remains the leading infectious cause of blindness globally, concentrated in Africa, yet the elimination endgame requires sustained trial investment in the SAFE strategy.
The Evidence 136 words · target 156
In the burden-versus-investment landscape of African health research, does the distribution of trachoma trials across African nations reveal a systematic research gap? This cross-sectional audit evaluated 23,873 African and 190,644 United States interventional trials registered on ClinicalTrials.gov through April 2026. Investigators computed the rate ratio comparing Africa to other regions as the primary estimand using registry metadata for each nation. Africa hosted 5 trachoma trials (0.0% of its portfolio) compared to 580 in the United States, yielding a 0.0-fold disparity in per-population investment. Temporal analysis showed 17.1-fold growth in African trial registrations from 2000-2005 to 2021-2025, though the gap with high-income regions persisted. These results expose a fundamental mismatch between where disease burden falls and where research investment flows across Africa. Interpretation is limited by reliance on ClinicalTrials.gov alone, which may undercount locally registered African studies.
Sentence Structure
Question
In the burden-versus-investment landscape of African health research, does the distribution of trachoma trials across African nations reveal a systematic research gap?
Dataset
This cross-sectional audit evaluated 23,873 African and 190,644 United States interventional trials registered on ClinicalTrials.
Method
gov through April 2026.
Primary Result
Investigators computed the rate ratio comparing Africa to other regions as the primary estimand using registry metadata for each nation.
Robustness
Africa hosted 5 trachoma trials (0.
Interpretation
0% of its portfolio) compared to 580 in the United States, yielding a 0.
Boundary
0-fold disparity in per-population investment.
Extra
Temporal analysis showed 17.
Extra
1-fold growth in African trial registrations from 2000-2005 to 2021-2025, though the gap with high-income regions persisted.
Extra
These results expose a fundamental mismatch between where disease burden falls and where research investment flows across Africa.
Extra
Interpretation is limited by reliance on ClinicalTrials.
Extra
gov alone, which may undercount locally registered African studies.